GlassScriptPhysician profile
Timothy J Roth
NPI 1144213604
$9,535.29
in general payments reported to CMS, 2019-2025
47 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,756 · 2020: $1,949 · 2021: $1,896 · 2022: $1,074 · 2023: $551 · 2024: $560 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,624.01 | 2019-2025 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $1,215.32 | 2019-2023 | |
| Amgen INC. | $733.53 | 2019-2024 | Repatha, Otezla, Prolia |
| Supernus Pharmaceuticals, INC. | $601.32 | 2019-2022 | |
| Corcept Therapeutics | $533.58 | 2024-2025 | Korlym |
| Lilly USA, LLC | $492.18 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $382.76 | 2019-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $381.45 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $311.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $277.94 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Therapeuticsmd, INC. | $227.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $202.24 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Lupin INC. | $202.03 | 2019-2020 | |
| Pfizer INC. | $181.43 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.